- Lung Cancer Diagnosis
Lung Cancer Diagnosis
An analysis of 70 studies finds that use of the diagnostic imaging procedure of fludeoxyglucose F18 (FDG)-positron emission tomography (PET) combined with computed tomography (CT) may not reliably distinguish benign disease from lung cancer in populations with endemic (high prevalence) infectious lung disease compared with nonendemic regions, according to a study in the September 24 issue of JAMA.
Depending on the risk for cancer, diagnostic guidelines suggest or recommend FDG combined with PET as a noninvasive test to assess the risk of cancer or benign disease, according to background information in the article.
Stephen A. Deppen, Ph.D., of the Tennessee Valley Healthcare System and Vanderbilt University Medical Center, Nashville, and colleagues conducted a meta-analysis to examine the accuracy of FDG-PET to diagnose lung lesions in regions with locally endemic infectious lung diseases. The researchers identified 70 studies that met criteria for inclusion in the analysis. Studies reported on a total of 8,511 nodules; 5,105 (60 percent) were malignant.
Pooled sensitivity of FDG-PET for diagnosing lung cancer was 89 percent and pooled specificity was 75 percent. There was a 16 percentage points difference in specificity in regions with endemic infectious lung disease (61 percent) compared with nonendemic regions (77 percent). Lower specificity was observed when the analysis was limited to rigorously conducted and well-controlled studies.
“FDG-PET for the diagnosis of lung cancer in patients who reside in a region with significant endemic infectious lung disease should be recognized as having lower specificity than previously reported. Knowledge of this reduction in specificity should limit the use of FDG-PET to diagnose lung cancer unless substantial institutional expertise in FDG-PET interpretation has been proven. Should low-dose CT screening for lung cancer become the diagnostic standard, knowledge of FDG-PET/CT performance is even more critical because the vast majority of indeterminate lung nodules detected through screening are benign,” the authors write.
DISCLAIMER: Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.
Contents © 2003-2018, BankixSystems.com. All rights reserved. Unauthorized reproduction strictly prohibited. Information based on best available resources. Opinions are current and subject to change.